Exploring Entera Bio Ltd. (ENTX) Investor Profile: Who’s Buying and Why?

You're looking at Entera Bio Ltd. (ENTX) and wondering who is actually buying into the oral peptide story, especially with the stock trading around $2.74 a share as of November 2025. Honestly, the investor profile is a fascinating mix: the general public holds a massive 55% stake, but institutional money is quietly building position, now accounting for about 14.11% of the shares outstanding. Are the hedge funds and specialist biotech investors seeing something the wider market is missing? Knoll Capital Management, LLC, for example, is the largest institutional holder with over 5.8 million shares, and you see firms like Citadel Advisors LLC increasing their stake by over 243% in a recent quarter, which is a clear signal. This accumulation is happening right after Entera Bio secured a critical FDA agreement in July 2025, allowing them to use total hip Bone Mineral Density (BMD) as the primary endpoint for the EB613 Phase 3 study-a massive de-risking event for their lead osteoporosis drug. Plus, with the company reporting a Q3 2025 net loss of only $3.2 million and extending its cash runway into mid-Q3 2026, the near-term liquidity risk is defintely lower. So, are these sophisticated buyers betting on the clinical data and the pathway to an oral anabolic treatment, or is this just a small-cap biotech gamble? Let's break down the key players and their core investment thesis.

Who Invests in Entera Bio Ltd. (ENTX) and Why?

You're looking at a clinical-stage biotech like Entera Bio Ltd. (ENTX), and the ownership structure tells you a clear story: this is a high-conviction, high-risk bet on a potential market-disruptor. The investor base is split between three main groups-retail investors, specialist institutions, and corporate partners-all drawn by the promise of the company's oral peptide delivery platform, not current earnings.

The direct takeaway is that individual investors hold the majority stake, but the institutional money is highly concentrated in a few key funds that specialize in life sciences catalysts. This ownership mix points to a stock driven by clinical trial milestones and regulatory news, not traditional value metrics.

Key Investor Types and Their Stakes

The investor profile for Entera Bio Ltd. is unusual for a publicly traded company, as the general public holds the largest piece of the pie. Individual investors, often referred to as retail, own a substantial 55% of the shares outstanding, a figure that gives them significant collective power over governance decisions.

Institutional investors, which include mutual funds, pension funds, and hedge funds, hold a smaller but still critical portion. As of the third quarter of 2025 (Q3 2025), institutional ownership of common stock was around 12.13%, representing a market value of approximately $14.37 million. The top holders are specialized players:

• Knoll Capital Management, LLC: The largest shareholder, holding 5,881,879 shares as of September 30, 2025.
• Point72 Asset Management, L.P.: A major hedge fund holding 1,178,443 shares as of the same date.
• OPKO Health, Inc.: A corporate partner holding a significant stake, which is often a strategic investment.

The presence of hedge funds, which control about 5.9% of the shares, signals interest in near-term, event-driven opportunities. They are looking for a quick pop on positive clinical data or a strategic partnership announcement. That's the quick math on who's in the game.

Investment Motivations: The Oral Peptide Catalyst

Investors aren't buying Entera Bio Ltd. for dividends-the company is a clinical-stage entity. They are buying the massive growth prospects tied to its platform for orally delivered peptides, which could transform the standard of care for chronic conditions. The core motivation is the lead candidate, EB613, an oral parathyroid hormone (PTH) anabolic tablet for osteoporosis.

The investment thesis is simple: if you can replace an injectable drug with a pill, you unlock a huge market. The recent Q3 2025 financial and clinical updates reinforced this outlook:

• Clinical Validation: Positive Phase 2 data showed EB613 produced a 3.1% increase in lumbar spine Bone Mineral Density (BMD) in early postmenopausal women after just six months, comparable to injectable therapies.
• Regulatory Clarity: The FDA agreed to a streamlined Phase 3 design, using BMD change as the primary endpoint, which significantly de-risks the regulatory path.
• Pipeline Expansion: The collaboration with OPKO Health, Inc. on an oral GLP-1/glucagon dual agonist for obesity provides a second, high-value shot on goal. This is a game-changer.

What this estimate hides, of course, is the risk of a Phase 3 failure, which is why the net loss for Q3 2025 was $3.2 million and total operating expenses were $3.3 million. You're betting on the science, not the balance sheet today. For a deeper dive on the company's long-term vision, check out their Mission Statement, Vision, & Core Values of Entera Bio Ltd. (ENTX).

Strategies: Long-Term Bets vs. Catalyst Trading

The composition of shareholders dictates the investment strategies at play. You see a clear split between long-term, conviction-based holding and short-term, event-driven trading.

The large institutional holders like Knoll Capital Management, LLC are clearly employing a long-term, venture-style strategy, taking a substantial position early and holding through the clinical development cycle. Meanwhile, the hedge funds are more likely to be in and out, trading the volatility that comes with a clinical-stage company. The cash runway, which is expected to last through the middle of Q3 2026 with $16.6 million on hand as of September 30, 2025, is a critical metric for all of them; it dictates the timeline for the next potential dilutive financing event. Any delay in the Phase 3 trial will increase the risk of a capital raise, which would impact all shareholder groups.

Institutional Ownership and Major Shareholders of Entera Bio Ltd. (ENTX)

You're looking at Entera Bio Ltd. (ENTX) and wondering who the big money players are-the institutions that signal confidence, or perhaps caution, in a biotech story. The direct takeaway is this: institutional ownership is relatively concentrated, but the retail investor base holds the majority stake, which is unusual for a NASDAQ-listed biotech.

As of late 2025, institutional investors hold a significant, yet minority, portion of the company. Specifically, institutional ownership sits at approximately 12.13% of the total shares outstanding, representing a total value of around $17.43 million. This is a small slice, considering individual investors-the general public-control a substantial 55% stake, giving them a unique level of influence over the company's direction.

Top Institutional Investors: Who's Buying?

The institutional profile for Entera Bio Ltd. (ENTX) is dominated by a few key players who have made meaningful, conviction-based bets. These aren't your typical broad-market index funds; they are often specialized hedge funds and investment managers focused on catalyst-driven, smaller-cap biopharma stories. The largest shareholder by a significant margin is Knoll Capital Management, LLC, which has a stake of roughly 13% of the company's shares outstanding. This kind of concentration means their moves are worth watching.

Here's the quick math on the top institutional holders, based on Q3 2025 filings (Form 13F):

To be fair, this table focuses on the largest funds. For a deeper dive into the company's foundational information, including its mission and how it generates revenue, you can check out Entera Bio Ltd. (ENTX): History, Ownership, Mission, How It Works & Makes Money.

Recent Shifts: Have Stakes Increased or Decreased?

We saw some notable portfolio rebalancing during the third quarter of 2025 (Q3 2025), which is typical as funds react to new clinical data and market conditions. The total number of institutional owners actually increased by 14.29% in the most recent quarter, suggesting new funds are initiating positions. That's defintely a positive sign of broadening interest.

However, the picture isn't uniform. Some key funds trimmed their positions. For example, Point72 Asset Management, L.P. significantly reduced its stake by selling 1,518,793 shares. On the flip side, Marshall Wace, Llp was a notable buyer, adding 627,330 shares. This tells you that while some large players took profits or moved on, others saw a fresh opportunity. The net change shows a mixed sentiment, but the overall institutional value is still substantial.

Impact of Institutional Investors on Strategy and Price

The role of these large investors in a clinical-stage biotech like Entera Bio Ltd. (ENTX) is critical. First, their presence lends credibility (social proof) to the company's technology-the oral delivery platform-and its lead drug candidate, EB613, which recently showed positive Phase 2 data in October 2025. This means their due diligence validated the science.

Second, the presence of hedge funds, which account for roughly 5.9% of the shares, means there are active investors looking for a near-term catalyst. The recent Q3 2025 financial results, which reported a net loss of $3.2 million and a cash runway expected through the middle of Q3 2026, plus the FDA's agreement on a single Phase 3 trial for EB613, are exactly the kind of catalysts these funds trade on. These investors often push management for clearer timelines and efficient capital use.

The risk, still, is concentration. If a major holder like Knoll Capital Management, LLC were to suddenly liquidate a large part of its 5.88 million shares, the stock price would definitely drop fast. That's the double-edged sword of high-conviction institutional ownership. For you, the action is clear: track the 13F filings of the top five holders quarterly. Finance: draft a simple tracker for the top five institutional holdings by next Friday.

Key Investors and Their Impact on Entera Bio Ltd. (ENTX)

You're looking at Entera Bio Ltd. (ENTX), a clinical-stage biotech, and trying to figure out who's funding its oral peptide technology. The short answer is: a mix of specialist hedge funds and, surprisingly, a strong base of individual investors. This unique ownership structure means the stock is highly sensitive to clinical milestones and retail sentiment, not just institutional block trades.

As of late 2025, the investment thesis is clearly tied to the progress of their lead candidate, EB613, the oral anabolic treatment for osteoporosis. The market is betting on the company's ability to move this program through its streamlined regulatory pathway, which the FDA agreed to in Q3 2025. That's the core opportunity here.

The largest institutional holder is Knoll Capital Management, LLC, which commands a significant position. As of September 30, 2025, Knoll Capital held 5,881,879 shares, representing roughly a 13% ownership stake in Entera Bio Ltd. (ENTX). That kind of concentrated ownership from a specialized fund tells you they have a high-conviction view on the company's platform technology-the oral delivery of large molecules.

The institutional roster also includes well-known names in the hedge fund world, which often signals a focus on near-term catalysts. For instance, Point72 Asset Management, L.P. and Marshall Wace, Llp are both notable holders. Here's a quick snapshot of the top institutional positions and their value as of Q3 2025:

What's defintely interesting is the retail side. Individual investors hold the largest overall slice of the pie, controlling a substantial 55% of the shares. This means the general public has a lot of influence on stock movements and even governance-related decisions. When you see a stock jump, like the 39% rise in one week in late 2025, it's often driven by this large, active retail base reacting to clinical news, not just the institutional traders.

Recent Investor Moves and the OPKO Health Partnership

The institutional money has been active, reflecting the clinical-stage risk/reward profile. In Q3 2025, we saw some significant moves. Marshall Wace, Llp, for example, initiated a new position, adding 627,330 shares. But still, not everyone is buying; Point72 Asset Management, L.P. cut their position by over 1.5 million shares during the same period. This kind of churn is typical for biotech as funds re-evaluate risk following pipeline updates.

The most important investor, however, isn't just a fund-it's OPKO Health, Inc., which holds an 8.1% stake as a strategic partner. This isn't just passive money. OPKO Health's involvement is a direct vote of confidence in the technology platform, and it comes with dedicated funding for a specific program. They provided direct investment that helped extend the company's cash runway into late 2026. This partnership has a tangible financial impact, as $8.0 million of the company's $16.6 million in cash and equivalents as of September 30, 2025, is restricted cash designated to fund their collaboration on the oral GLP-1/glucagon candidate (OPK-88006) through Phase 1 studies. That's a clear, non-dilutive source of capital for a key pipeline asset.

Here's the quick math on why investors are focused on the pipeline: The company is pre-revenue, reporting a net loss of $3.2 million in Q3 2025. This loss is manageable because their total operating expenses were only $3.3 million for the quarter, but it underscores the need for clinical success to justify the valuation. The investments are purely a bet on the future commercial success of the oral peptide technology, particularly EB613, which is now preparing for a single, 24-month multinational Phase 3 study. You can read more about the company's foundation and strategy here: Entera Bio Ltd. (ENTX): History, Ownership, Mission, How It Works & Makes Money.

The influence of these investors is less about activism and more about validation. When a fund like Knoll Capital or a partner like OPKO Health commits a large amount of capital, it validates the science for other investors, which is crucial for a clinical-stage company. The buying and selling activity is simply a reflection of their conviction in the probability of a successful Phase 3 trial for EB613.

• Knoll Capital Management: Largest institutional holder, high-conviction biotech bet.
• OPKO Health, Inc.: Strategic partner, provides dedicated $8.0 million in restricted cash funding.
• Individual Investors: Control 55% of shares, driving significant stock volatility on news.

What this estimate hides is the binary risk of clinical trials. The stock will move on every data release, so watch those R&D expenses, which were $1.6 million in Q3 2025, as they show the pace of pipeline progress.

Market Impact and Investor Sentiment

You're looking at Entera Bio Ltd. (ENTX) and trying to figure out if the big money is buying, holding, or running for the hills. The short answer is that sentiment is cautiously optimistic, but it's a story dominated by individual investors, not just institutions.

Insider sentiment for Entera Bio Ltd. is defintely Positive right now, which is a powerful signal. Over the last year, 11 different insiders have been buying, which shows management and board members are putting their own capital on the line. To be fair, though, the real power lies with the retail crowd: individual investors hold a massive 55% stake in the company, meaning the general public has the most influence on governance and stock movement. Institutional investors, the big funds and hedge funds, only account for about 14.11% of the stock. That's a low number for a public biotech, but it's also a sign of potential upside if a few large funds decide to jump in.

Here's a quick look at the top institutional players as of the Q3 2025 filings:

• Knoll Capital Management: Largest shareholder with a 13% stake.
• Point72 Asset Management, L.P.: Held over 1.17 million shares.
• Marshall Wace, Llp: Recently established a new position with 627,330 shares.

The total value of all institutional holdings is roughly $25 million, so while the percentage is small, the capital commitment is real. You can check out the full story on how the company got to this point in Entera Bio Ltd. (ENTX): History, Ownership, Mission, How It Works & Makes Money.

Recent Market Reactions to Key Investor Moves

The stock market's reaction to Entera Bio Ltd. is less about a single large institutional trade and more about the clinical pipeline's progress. This makes sense for a clinical-stage biopharmaceutical company-the science is the catalyst, not the quarterly 13F filings.

For example, the stock rose 3.5% in premarket trading on October 23, 2025, following positive Phase 2 data for its lead candidate, EB613, an oral treatment for osteoporosis. That's a clear market signal that clinical success trumps minor shifts in institutional ownership. More recently, on November 19, 2025, the stock price gained 1.92%, closing at $2.65.

When the company announced its Q3 2025 results on November 14, 2025, the reaction was muted, with shares trading down about 1.1% to $2.71. This is despite a beat on earnings, where the company reported an EPS of ($0.07), which was better than the consensus estimate of ($0.09). This tells you the market is looking past the small quarterly numbers and focusing on the long-term clinical runway.

Here's the quick math on the Q3 2025 financials: The net loss for the quarter was $3.2 million, and the company reported $16.6 million in cash and equivalents, providing a cash runway through the middle of Q3 2026. This cash position is what investors are really watching, as it funds the critical Phase 3 trial for EB613.

Analyst Perspectives and the $10.00 Target

When you look at Wall Street's official perspective on Entera Bio Ltd., the picture is one of high-risk, high-reward. The consensus analyst rating is a 'Moderate Buy,' but this masks a deep divide: one analyst has a 'Strong Buy' rating, and another has a 'Sell' rating. It's a binary bet on the success of their oral peptide delivery platform.

The average 12-month price target from analysts is a uniform $10.00. This target implies a massive upside of nearly 297% from a recent price of $2.52, which is why the stock attracts speculative growth investors. The analysts are betting on the successful advancement of EB613, which the FDA has agreed can use Bone Mineral Density (BMD) as the primary endpoint for its single, multinational Phase 3 study. This FDA agreement is a major de-risking event that fuels the bullish price target.

The impact of key investors, particularly Knoll Capital Management's 13% stake, is that they provide a foundation of committed capital. Their presence, alongside other funds like Point72 Asset Management, L.P., lends credibility to the company's technology-it shows that smart money believes in the oral delivery of large molecules, which is a game-changer if it works consistently. If the Phase 3 trial data is positive, you'll see a rush of institutional buying that will make the current $10.00 target look conservative.

The key action for you: Track the EB613 Phase 3 updates; that's the only thing that changes the valuation. The rest is noise.